Denali Advisors LLC Lowers Position in Amdocs Limited (NASDAQ:DOX)

Denali Advisors LLC lessened its holdings in shares of Amdocs Limited (NASDAQ:DOX) by 30.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,610 shares of the technology company’s stock after selling 2,508 shares during the quarter. Denali Advisors LLC’s holdings in Amdocs were worth $478,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pzena Investment Management LLC increased its stake in Amdocs by 12.3% in the third quarter. Pzena Investment Management LLC now owns 6,363,739 shares of the technology company’s stock valued at $556,700,000 after acquiring an additional 696,136 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Amdocs by 123.2% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 759,136 shares of the technology company’s stock worth $66,409,000 after purchasing an additional 419,045 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amdocs by 1,207.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 271,701 shares of the technology company’s stock valued at $23,768,000 after purchasing an additional 250,918 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Amdocs by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,633,733 shares of the technology company’s stock valued at $143,498,000 after buying an additional 158,843 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in Amdocs by 338.3% in the 3rd quarter. Rice Hall James & Associates LLC now owns 167,023 shares of the technology company’s stock worth $14,611,000 after buying an additional 128,919 shares during the last quarter. Hedge funds and other institutional investors own 92.02% of the company’s stock.

Amdocs Stock Performance

NASDAQ:DOX opened at $87.74 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.20 and a current ratio of 1.16. Amdocs Limited has a fifty-two week low of $74.41 and a fifty-two week high of $94.04. The business has a 50 day moving average price of $86.21 and a 200-day moving average price of $86.75. The firm has a market cap of $9.91 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.47 and a beta of 0.71.

Amdocs (NASDAQ:DOX) last announced its quarterly earnings results on Tuesday, February 4th. The technology company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.19). Amdocs had a return on equity of 18.89% and a net margin of 10.19%. Equities research analysts predict that Amdocs Limited will post 6.21 earnings per share for the current year.

Amdocs Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Sunday, April 20th. Investors of record on Monday, March 31st will be issued a dividend of $0.527 per share. This represents a $2.11 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Amdocs’s previous quarterly dividend of $0.48. Amdocs’s payout ratio is currently 48.72%.

Analyst Upgrades and Downgrades

DOX has been the topic of a number of recent research reports. Barclays reduced their price target on shares of Amdocs from $113.00 to $111.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Oppenheimer increased their target price on shares of Amdocs from $98.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Amdocs from a “strong-buy” rating to a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.20.

Amdocs Profile

Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.